Compare
Cognition Therapeutics Inc vs PharmaCyte Biotech, Inc. vs Senti Biosciences Holdings, Inc. vs Ocugen, Inc.
| Latest fiscal year | Cognition Therapeutics Inc CGTX | PharmaCyte Biotech, Inc. PMCB | Senti Biosciences Holdings, Inc. SNTI | Ocugen, Inc. OCGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-04-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $22.0K | $4.41M |
| Revenue growth (YoY) | n/a | n/a | n/a | +8.8% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/m |
| Net margin | n/a | n/a | n/m | n/m |
| Net income | -$23.49M | -$19.42M | -$61.44M | -$67.85M |
| EPS (Diluted) | -$0.32 | -$2.77 | -$2.73 | n/a |
| Operating cash flow | -$24.59M | -$5.15M | -$43.44M | -$56.96M |
| Free cash flow | n/a | n/a | -$43.64M | -$57.15M |
| Cash & equivalents | $36.81M | $18.60M | $16.42M | n/a |
| Total assets | $48.39M | $46.75M | $51.22M | $43.52M |
| Total liabilities | $14.12M | $11.77M | $45.63M | $55.68M |
| Shareholders' equity | $34.27M | $33.29M | $5.59M | -$12.17M |
| Return on year-end equity | -68.5% | -58.3% | n/m | n/a |
| Shares outstanding | 88.90M | 10.74M | 30.88M | 312.38M |
Revenue, most recent five fiscal years
| Fiscal year | Cognition Therapeutics Inc | PharmaCyte Biotech, Inc. | Senti Biosciences Holdings, Inc. | Ocugen, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2026-04-30 | $22.0K Ended 2025-12-31 | $4.41M Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2025-04-30 | $0 Ended 2024-12-31 | $4.05M Ended 2024-12-31 |
| 2 years earlier | n/a | $0 Ended 2024-04-30 | $1.98M Ended 2023-12-31 | $6.04M Ended 2023-12-31 |
| 3 years earlier | n/a | $0 Ended 2023-04-30 | $3.29M Ended 2022-12-31 | $2.49M Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2022-04-30 | $2.29M Ended 2021-12-31 | n/a |